Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) announced positive topline results from the pivotal study designed to support its planned FDA PMA submission for approval to market its next-generation Perimeter B...

November 20, 2024

Executive Moves

MOBILion launches proteomics advisory board

Closely-held MOBILion Systems announced the formation of a proteomics advisory board to provide strategic guidance as the company advances the development of its next-generation high-resolution mass spectrometry...

November 20, 2024

Developments

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS). The company states that NUZ-001 reduces the...

November 19, 2024

Developments

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Adverum Biotechnologies (NASDAQ:ADVM) announced topline 52-week results from its LUNA Phase 2 trial, new four-year long-term follow-up data from its OPTIC study, and key design elements for its pivotal program. Both the...

November 18, 2024

Developments

Therma Bright to spin off consumer product portfolio creating new company

Therma Bright (TSXV:THRM; QTCQB:TBRIF) announced plans to spin off its consumer product portfolio into a separate publicly traded company during the first half of 2025. The spin-off transaction will be subject to...

November 18, 2024

Executive Moves

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

MindMed (NASDAQ:MNMD) has appointed Gregg Pratt, Ph.D., as chief regulatory and quality assurance officer. Dr. Pratt will oversee the company’s regulatory and quality functions, as well as its product registration...

November 18, 2024

Developments

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...

November 15, 2024

Executive Moves

Opthea names Kathy Connell to BOD

Opthea (ASX/NASDAQ:OPT) announced the appointment of Kathy Connell to its board of directors as a non-executive director. Ms. Connell brings extensive business development expertise across pharmaceutical, vaccine...

November 15, 2024

Developments

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...

November 14, 2024

Developments

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...

November 13, 2024

Developments

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) announced positive clinical data from the fifth cohort of its RESOLVE Phase 1b/2a trial, a multi-center, open-label, dose-escalation study to evaluate the safety...

November 13, 2024

Developments

Lipella’s liposomal delivery platform granted patent by USPTO

Lipella Pharmaceuticals (NASDAQ:LIPO) announced that the U.S. Patent and Trademark Office (USPTO), has issued a patent for its proprietary liposomal delivery platform today. Lipella reports that the patent protects its...

November 12, 2024

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

MOBILion launches proteomics advisory board

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Therma Bright to spin off consumer product portfolio creating new company

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

Opthea names Kathy Connell to BOD

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Lipella’s liposomal delivery platform granted patent by USPTO

General

More